
Regeneron Pharmaceuticals (NASDAQ:REGN) expects its three largest growth drivers to continue supporting revenue growth, while planning higher research and development spending and preparing for a specialty drug launch, executives said at the Jefferies Healthcare Conference.
Chief Financial Officer Chris Fenimore said third-quarter revenue was approximately $5.1 billion, up 36% from a year earlier. Adjusted earnings per share were just over $20, an increase of about 70%.
EYLEA HD generated approximately $700 million in the quarter, while cancer drug LIBTAYO recorded about $550 million in global sales, Fenimore said. Global sales of DUPIXENT were approximately $6.5 billion, including about $5 billion in the United States.
Fenimore said Regeneron fully repaid an approximately $3 billion development balance associated with the DUPIXENT alliance in the second quarter. The company saw the full benefit in the third quarter and expects to benefit again in the fourth quarter, as well as in year-over-year comparisons for the first two quarters of 2027.
EYLEA HD Outlook and Patent Review
Fenimore said the branded eye-care market has stabilized after copay assistance constraints affected patients beginning in 2025, although affordability challenges remain. He expects the overall market to grow at a low-single-digit rate, supported by an aging population and diagnoses of diabetic retinal disease.
Regeneron remains optimistic about securing U.S. approval for an EYLEA HD prefilled syringe by year-end, Fenimore said. He expects the device to provide an additional boost to adoption, though he said it was difficult to estimate its magnitude. Some providers have indicated they are waiting for the syringe before using the drug more broadly in their practices.
Ryan Crowe, senior vice president of investor relations and strategic analysis, said oral arguments in a post-grant review of an EYLEA HD patent are scheduled for Dec. 4, with a decision due by early March 2027. Crowe said Regeneron declined an offer from Alvotech to mutually withdraw the review and believes its case for the patent’s validity is compelling.
Crowe said other issued or pending patents could support EYLEA HD exclusivity into the late 2030s or the 2040s. He added that the company could not provide certainty about when biosimilars might launch.
Spending and Business Development
Fenimore declined to provide financial guidance but said Regeneron expects its major products to drive further top-line growth. He noted that the company had previously projected a mid-teens percentage increase in research and development investment year over year, which would affect operating leverage in the short term.
The planned launch of cemdisiran for myasthenia gravis, a new specialty neurology area for Regeneron, will also require selling, general and administrative investment, he said.
On acquisitions, Fenimore said the company is open to external deals but remains disciplined on valuation. He also said Regeneron believes its internal pipeline can diversify revenue and support growth around the turn of the decade. Under its expanded alliance with Sanofi, the companies could consider joint external opportunities, although they would assess them individually, he said.
Pipeline Plans
Executives highlighted early-stage opportunities in liver disease, ovarian cancer and postural orthostatic tachycardia syndrome, or POTS.
For its CIDEB program, Regeneron plans a one-year Phase 2b study with a primary endpoint measuring liver fat reduction at week 26 and biopsy data at week 52 assessing fibrosis and MASH resolution, Crowe said. The company intends to discuss the study design with the Food and Drug Administration, including whether a noninvasive endpoint could be incorporated.
About Regeneron Pharmaceuticals (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.
